Introduction main ubiquitin ligase for p53 is the oncogene MDM2 (also known as HDM2 when referring specifically to the human The p16 INK4a protein was initially cloned as a protein associated gene) (10). Concurring with the role of MDM2 as a repressor with the cyclin D-dependent kinase CDK4, and it was shown of p53, tumors overexpressing MDM2 do not accumulate to be an efficient inhibitor of the CDK4 kinase activity (1). detectable p53 levels and do not carry mutations in the Several proteins closely related to p16 INK4a have subsequently p53 gene (11). Protein p19 ARF associates with MDM2 and been identified that together form the INK4 family: p16 INK4a , sequesters it into the nucleoli (12,13). Theses two functions, p15 INK4b , p18 INK4c and p19 INK4d (2). The four INK4 proteins binding to MDM2 and nucleolar localization, are essential for have similar biochemical activities, all of them binding and p19 ARF -mediated stabilization of p53 (12,13). The p19 ARF /p53 inhibiting CDK4 and its related kinase CDK6. The relevant pathway is also thought to be deregulated in the large majority feature that characterizes each INK4 protein appears to be its of human tumors either by loss of p19 ARF or p53, or by specific transcriptional regulation. In particular, the expression overexpression of MDM2 ( Figure 2 ). of p16 INK4a is activated by oncogenic stresses (see below),
The above-described pathways can be simultaneously while the expression of p15 INK4b is upregulated by the negative deregulated by homozygous deletion of the entire INK4/ARF growth factor transforming growth factor β (3).
locus (see below), or they can be deregulated by a combination One of the most surprising discoveries of recent years of mutagenic events, such as amplification of cyclin D1 and has been the realization that the INK4a locus contains an loss of p53. Recently, a novel mechanism of deregulation has overlapping gene named ARF and encoding p19 ARF (also called been identified in relation to the Bmi1 oncogene. Bmi1 belongs p14 ARF when referring specifically to the human version) (4-to the Polycomb family of chromatin silencers, and when 7). The INK4a and ARF genes have their own separate overexpressed is able to repress simultaneously the transcrippromoters, each of which produces a different transcript: the tional activity of the INK4a and ARF promoters (14). INK4a transcript is formed by exons 1α, 2 and 3; and the It is important to emphasize the existence of multiple levels ARF transcript is formed by exons 1β, 2 and 3 (Figure 1) .
of crosstalk between the p16 INK4a /Rb and p19 ARF /p53 pathways. Although exons 2 and 3 are common to INK4a and ARF For example, p53 transcriptionally activates the expression of transcripts, they are read in different frames and, consequently, p21 Cip1 which, in turn, inhibits the CDK2/A-E kinases prethe corresponding proteins do not share amino acid sequence venting the full phosphorylation of Rb (15). Also, MDM2 can homology. The p19 ARF protein has turned out to be a negative interfere with the growth-suppressive activity of Rb (16). These and other additional levels of regulation complicate the regulator of the p53-destabilizing oncogene MDM2 (8). The interpretation of the effects that particular alterations of these structure of the INK4a/ARF locus is conserved among humans, pathways may have on cell proliferation and apoptosis. mice and rats (4-7,9), but an equivalent to p19 ARF is absent in the loci encoding the other three members of the INK4
The INK4a/ARF locus as a sensor of oncogenic stress family. It is also important to mention that the INK4b gene is located immediately upstream of the INK4a/ARF locus
The normal levels of expression of p16 INK4a and p19 ARF are extremely low in most tissues. In mice, p16 INK4a and p19 ARF (Figure 1) . 
2). (ii) Intragenic mutation. This type of
It is interesting to mention that a number of studies have inactivation mechanism is rather infrequent in the INK4a/ARF found a significant proportion of INK4a/ARF intragenic locus. Most point mutations occur in the second exon common mutations in lung and liver tumors induced with 3-methylcholfor p16 INK4a and p19 ARF , usually affecting the amino acid anthrene (7 and 19%, respectively; Table I ) (32-34), but not sequence of both proteins. Nevertheless, a fraction of mutations in similar tumors induced with other carcinogens (29, 30, 35) . occur in exon 1α, thus affecting exclusively the p16 INK4a This is a remarkable observation considering the low incidence coding region. (37-39). In any case, one study has analyzed the status of The status of the INK4a/ARF locus in murine tumors has p16 INK4a , p15 INK4b , CDK4, cyclin D1 and Rb in the same set been analyzed in a number of studies (summarized in Table I ).
of lymphomas, reaching the conclusion that 75% of the Several interesting points can be made from the available data.
radiation-induced T-cell lymphomas have alterations in one or In first place, the incidence of alterations in the murine INK4a/ several components of this pathway (40) . Regarding B-cell ARF locus appears rather low in primary solid tumors compared lymphomas developed by transgenic mice expressing the Myc to the high incidence of alterations found in tumor cell lines. A similar situation has been encountered studying human oncogene, there is strong evidence indicating that p19 ARF is a Mice contain a transgene that expresses oncogenic Ras under the tyrosinase promoter (melanocyte specific). b In the same period, only 2% of the control tyr-ras mice develop melanomas. c Mice contain two transgenes that allow the inducible expression of oncogenic Ras by doxycyclin in melanocytes. d Mice contain a transgene formed by an avian retrovirus receptor under the nestin promoter (glia specific), and are subsequently infected with an avian retrovirus carrying an activated EGF receptor. e In the same period, none of the control Ntv-a(ϩEGFR*) mice develop gliomas. f Mice contain a transgene that expresses the Myc oncogene under the Eµ promoter (B-lymphocyte specific). g Control Eµ-myc mice have a 50% lethality before 5 months.
the key tumor suppressor inactivated by the deletion of the such as overexpression of cyclins D, E or A (45), that make these tumor cells insensitive to the anti-proliferative effects of INK4a/ARF locus (41) (42) (43) .
Finally, it is interesting to mention that those tumors that p16 INK4a . retain a functional INK4a/ARF locus, usually manifest a dramatic upregulation of its expression. In particular, it has INK4a/ARF alleles and cancer susceptibility in mice been observed that p16 INK4a is significantly accumulated in skin carcinomas (31, 44, 45) , lung tumors (35) and bladder
Many observations indicate that cancer susceptibility is under complex multigenic influences. For some particular types of carcinomas (46). The upregulation of p16 INK4a can be explained by the continued presence of an oncogenic stress, such as tumors it has been possible to map susceptibility loci with a high resolution in the mouse genome. One of the susceptibility activated Ras (see above), in combination with other alterations, loci for chemically induced plasmacytomas (a B-lymphocyte Concluding remarks malignancy) has been proposed to correspond to the INK4a/ The role of the INK4a/ARF locus in tumor suppression is now ARF locus (47) . Similarly, a susceptibility locus for chemically relatively well understood. 
